Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $200 million, and for the full year 2025, it was $1 billion, which included a one-time $275 million upfront payment from the Sobi royalty repurchase agreement [17] - Syfovre net product revenue for Q4 was $155 million and $587 million for the full year 2025, with total injections growing approximately 17% year-over-year [8][17] - Empaveli reported U.S. net product revenue of $35 million for Q4 and $102 million for the full year 2025, indicating strong early market receptivity [19] Business Line Data and Key Metrics Changes - Syfovre experienced a modest decline in full-year revenue compared to 2024, primarily due to elevated use of free goods, but underlying demand remains strong [8] - Empaveli achieved over 5% market penetration after its first full quarter, significantly outpacing other rare nephrology launches [6][10] - The company is advancing pivotal trials in nephrology for Empaveli, targeting focal segmental glomerulosclerosis and delayed graft function [7] Market Data and Key Metrics Changes - Syfovre continues to lead the geographic atrophy market, with strong physician and patient preference due to its differentiated profile [8] - Empaveli's launch has been supported by favorable payer access, with 95% of published policies reimbursing to label or with minimal restrictions [10] Company Strategy and Development Direction - The company focuses on three strategic pillars: strengthening Syfovre's leadership in geographic atrophy, driving growth with Empaveli across rare kidney diseases, and advancing an innovative pipeline [4] - The introduction of a best-in-class prefilled syringe and an AI-enabled approach for Syfovre is expected to enhance treatment accessibility and workflow efficiency [5][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term value creation and the ability to self-fund the pipeline due to a strong balance sheet and growing commercial revenue base [7][23] - The company anticipates a modest inventory reduction in Q1 2026 alongside typical seasonal dynamics, indicating a disciplined approach to inventory management [18] Other Important Information - The company ended 2025 with $466 million in cash and cash equivalents, providing substantial flexibility to fund operations [20] - A milestone payment of $25 million was triggered by Sobi's European Commission approval for Aspaveli in C3G and primary IC-MPGN [21] Q&A Session Summary Question: Empaveli launch and growth potential - Management highlighted that Empaveli is on a clear path to blockbuster status, with a focus on broadening accounts and improving patient identification [25] - The epidemiology for C3G and IC-MPGN is approximately 5,000 patients in the U.S., with expectations of reaching up to 50% penetration [26][27] Question: Syfovre's five-year GALE data - The five-year data shows that Syfovre can delay progression of geographic atrophy by approximately 1.5 years, which is significant for patients [31][32] Question: Empaveli penetration and competitive dynamics - Management expects steady growth in Empaveli's adoption, with a clear differentiation in the pediatric segment and IC-MPGN [36][38] Question: Prefilled syringe impact on practice dynamics - The prefilled syringe is expected to enhance practice efficiency and patient treatment, providing a competitive advantage [48][50] Question: Free goods and patient assistance dynamics - The company remains committed to supporting patients who cannot afford copays, which has been integral to their strategy [98][99]